Drug intelligence / Profile preview

Setebid

Development stage: Unknown
Lead developer: AVN Ayurveda Formulations
Administration: Oral

Overview

**Setebid** is a proprietary oral Ayurvedic polyherbal tablet marketed by AVN Ayurveda for management of **type 2 diabetes mellitus** and prediabetes. The formulation contains concentrated botanical extracts including turmeric, Indian gooseberry, jamun, guggul, clearing nut, black catechu, tree turmeric, *Humboldtia vahliana*, mango seed, chebulic myrobalan, and *Cyperus rotundus*. It is promoted as an anti-hyperglycemic and antioxidant preparation intended to support glucose control, cellular glucose uptake, insulin activity, and protection from diabetes-associated oxidative and microvascular complications; these are product claims rather than a clinically established target-specific mechanism.

Brand names: Setebid
Other names: Setebid Tablets

Beyond the preview

Go deeper on Setebid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Setebid.

Explore the full profile